Effects of IVF Hormonal Therapy on Endometrial Health
Impact of Controlled Ovarian Stimulation and Luteal Phase Support on Endometrial Receptivity and Endometrial Senescent Cell Pathological Accumulation: Pilot Study
This study is testing how different hormonal treatments used in IVF affect the health of the uterus to see if they can improve the chances of successful implantation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 45 Years |
| Sex | Female |
| Sponsor | Fundación IVI Academic / other |
| Locations | 1 site (Valencia) |
| Trial ID | NCT06280560 on ClinicalTrials.gov |
What this trial studies
This observational study investigates how hormonal therapies used in in vitro fertilization (IVF) impact endometrial receptivity and the accumulation of senescent cells in the endometrium. It compares outcomes from controlled ovarian stimulation combined with luteal phase support, hormonal replacement therapy, and natural cycles. The study aims to understand whether elevated hormone levels during these treatments lead to changes in the endometrial environment that could affect implantation success. By analyzing these effects, the research seeks to provide insights into optimizing IVF protocols for better patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include subfertile women aged 18-45 undergoing IVF treatment with a BMI between 18.5 and 30.
Not a fit: Patients with uterine diseases affecting the endometrial cavity or those with systemic or endocrine disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved IVF protocols that enhance implantation rates and pregnancy outcomes for patients.
How similar studies have performed: While the specific approach of this study is novel, previous studies have indicated that hormonal levels can significantly affect endometrial receptivity, suggesting potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Study group (subfertile IVF patients). * Inclusion Criteria: Women aged 18-45 years, BMI ≥ 18.5- 30. * Exclusion criteria: Women presenting any uterine disease that affects the endometrial cavity, or with a thin or irregular endometrium, altered karyotypes, thrombophilias, or uncorrected systemic or endocrine diseases will be excluded. Endometrial receptivity reference group (oocyte donors). * Inclusion criteria: women aged between 18 and 35 years, BMI ≥ 18.5- 25. * Exclusion criteria: Any cases of DIU presence, hormonal contraceptives at least during the last three months, altered karyotypes, thrombophilias, or uncorrected systemic or endocrine diseases will be excluded.
Where this trial is running
Valencia
- IVI-RMA Valencia Clinic — Valencia, Spain (Recruiting)
Study contacts
- Principal investigator: Francisco Domínguez Hernández, PhD — IVI Foundation, Valencia, Valencia, Spain
- Study coordinator: Francisco Domínguez Hernández, PhD
- Email: francisco.dominguez@ivirma.com
- Phone: +34963903305
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.